Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted ex...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255799/full |
| _version_ | 1797692539631828992 |
|---|---|
| author | Hong Zhou Hong Zhou Hong Zhou Yipeng Ma Yipeng Ma Fenglan Liu Fenglan Liu Bin Li Bin Li Dongjuan Qiao Dongjuan Qiao Peigen Ren Mingjun Wang Mingjun Wang |
| author_facet | Hong Zhou Hong Zhou Hong Zhou Yipeng Ma Yipeng Ma Fenglan Liu Fenglan Liu Bin Li Bin Li Dongjuan Qiao Dongjuan Qiao Peigen Ren Mingjun Wang Mingjun Wang |
| author_sort | Hong Zhou |
| collection | DOAJ |
| description | New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4+ T cells via major histocompatibility complex class II (MHC-II) and to CD8+ T cells via major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research. |
| first_indexed | 2024-03-12T02:29:07Z |
| format | Article |
| id | doaj.art-87acc4442ee84ef99e023f986e722579 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T02:29:07Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-87acc4442ee84ef99e023f986e7225792023-09-05T09:20:55ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12557991255799Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatmentHong Zhou0Hong Zhou1Hong Zhou2Yipeng Ma3Yipeng Ma4Fenglan Liu5Fenglan Liu6Bin Li7Bin Li8Dongjuan Qiao9Dongjuan Qiao10Peigen Ren11Mingjun Wang12Mingjun Wang13Center for Energy Metabolism and Reproduction, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Innovation Immunotechnology Co., Ltd, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Institute for Innovation and Translational Medicine, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Innovation Immunotechnology Co., Ltd, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Institute for Innovation and Translational Medicine, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Innovation Immunotechnology Co., Ltd, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Institute for Innovation and Translational Medicine, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Innovation Immunotechnology Co., Ltd, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Institute for Innovation and Translational Medicine, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Innovation Immunotechnology Co., Ltd, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Institute for Innovation and Translational Medicine, Shenzhen, ChinaCenter for Energy Metabolism and Reproduction, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Innovation Immunotechnology Co., Ltd, Shenzhen, ChinaDepartment of Research and Development, Shenzhen Institute for Innovation and Translational Medicine, Shenzhen, ChinaNew York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4+ T cells via major histocompatibility complex class II (MHC-II) and to CD8+ T cells via major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255799/fullCTANY-ESO-1cancer vaccineimmunotherapysolid cancer |
| spellingShingle | Hong Zhou Hong Zhou Hong Zhou Yipeng Ma Yipeng Ma Fenglan Liu Fenglan Liu Bin Li Bin Li Dongjuan Qiao Dongjuan Qiao Peigen Ren Mingjun Wang Mingjun Wang Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment Frontiers in Immunology CTA NY-ESO-1 cancer vaccine immunotherapy solid cancer |
| title | Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment |
| title_full | Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment |
| title_fullStr | Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment |
| title_full_unstemmed | Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment |
| title_short | Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment |
| title_sort | current advances in cancer vaccines targeting ny eso 1 for solid cancer treatment |
| topic | CTA NY-ESO-1 cancer vaccine immunotherapy solid cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255799/full |
| work_keys_str_mv | AT hongzhou currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT hongzhou currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT hongzhou currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT yipengma currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT yipengma currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT fenglanliu currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT fenglanliu currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT binli currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT binli currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT dongjuanqiao currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT dongjuanqiao currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT peigenren currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT mingjunwang currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment AT mingjunwang currentadvancesincancervaccinestargetingnyeso1forsolidcancertreatment |